-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
About 15%-20% of aggressive early breast cancer patients overexpress human epidermal growth factor receptor 2 (HER2), and HER2 overexpression is associated with a higher recurrence rate than HER2 negative.
The recurrence rate of breast cancer stage I HER2-positive breast cancer is between 10% and 30%
The purpose of the ATEMPT test is to determine whether trastuzumab emtansine (T-DM1) is less toxic than paclitaxel + trastuzumab (TH) in the treatment of stage I HER2-positive breast cancer, and obtains clinically acceptable results.
Recruited patients with stage I breast cancer diagnosed as HER2-positive, randomly assigned to T-DM1 group or TH group at 3:1, and received T-DM1 (3.
Survival prognosis of patients treated with T-DM1: A 3-year iDFS; B 3-year RFI; C iDFS for patients with different tumor sizes; D iDFS for patients with different HR status
Survival prognosis of patients treated with T-DM1: A 3-year iDFS; B 3-year RFI; C iDFS for patients with different tumor sizes; D iDFS for patients with different HR statusA total of 497 patients were recruited and received protocol treatment (383 in the T-DM1 group and 114 in the TH group).
The incidence of CRT in the T-DM1 group and TH group was 46% and 47%, respectively .
Overall QOL of patients in the two treatment groups
Overall QOL of patients in the two treatment groupsIn summary, the results of this study show that for patients with HER2-positive stage I breast cancer, compared with paclitaxel combined with trastuzumab therapy, adjuvant T-DM1 therapy can achieve an excellent 3-year non-invasive disease survival rate for one year.
For patients with HER2-positive stage I breast cancer, compared with paclitaxel combined with trastuzumab therapy, adjuvant T-DM1 treatment for one year can obtain an excellent 3-year non-invasive disease survival rate without increasing clinically relevant toxic events Incidence rate.
Original source:
Tolaney Sara M,Tayob Nabihah,Dang Chau et al.
Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial
Leave a message here
